Efficacy of the combination of ipilimumab and nivolumab following progression on pembrolizumab in advanced melanoma with poor risk features

EUROPEAN JOURNAL OF CANCER

ELSEVIER SCI LTD

1. Pfizer
2. BMS
3. Novartis
4. MSD
5. National Institute for Health Research Royal Marsden Hospital and Institute of Cancer Research Biomedical Research Centre (NIHR RMH/ICR BRC)